作者:Joel Slade、David Parker、Michael Girgis、Martin Mueller、James Vivelo、Hui Liu、Joginder Bajwa、Guang-Pei Chen、Joseph Carosi、Paul Lee、Apurva Chaudhary、Dana Wambser、Kapa Prasad、Kathryn Bracken、Karl Dean、Helmut Boehnke、Oljan Repič、Thomas J. Blacklock
DOI:10.1021/op050165y
日期:2006.1.1
A practical synthesis of the peptide deformylase inhibitor LBM415, (2S)-N-(5-fluoro-1-oxido-2-pyridinyl)-1-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxohexyl]-2-pyrrolidinecarboxamide, magnesium salt 11, is described. The key chiral intermediate, (2S)-N-(5-fluoro-2-pyridinyl)-1-[(2R)-2-[[formyl(phenylmethoxy)amino]methyl]-1-oxohexyl]-2-pyrrolidinecarboxamide 8, was made by coupling the corresponding amino
肽去甲酰基酶抑制剂LBM415,(2 S)-N-(5-氟-1-氧化-2-吡啶基)-1-[(2 R)-2-[(甲酰基羟氨基)甲基] -1-的实用合成描述了氧己基] -2-吡咯烷甲酰胺,镁盐11。关键的手性中间体,(2 S)-N-(5-氟-2-吡啶基)-1-[(2 R)-2-[[甲酰基(苯基甲氧基)氨基]甲基] -1-氧己基] -2-吡咯烷甲酰胺8,按与相应的氨基酸偶联制成7与甲酰胺25从制备升-脯氨酸和2-氨基-5-氟吡啶。吡啶氮氧化后,对苄基进行选择性氢解得到原料药的游离酸,将其用氯化镁原位转化为镁盐。得到的产物的总产率为16%,ee> 99%。